Investor Relations
Living Cell Technologies is a fast growing public bioscience company listed on the both the Australian Stock Exchange and the International OTCQX.
With over 1200 shareholders from Australasia, Europe and the United States of America, LCT is focused on building an global cellular theraputics business that will have its own capabilities providing live cell therapies in Asia Pacific, USA and Europe through the commercialisation of products currently being tested.
Investor Overview
Annual Reports
Download LCT’s 2007 Annual Report [3.14mb PDF]
Download 2006 Annual Report Part 1 - Editorial [2.43mb PDF]
Corporate Governance
For further information on the monitoring of the business and affairs of LCT please visit our Corporate Governance page.
Share Listing Information
For futher information on the OTCQX listing and ADR’s please click here.
Media Resources
For press releases, newsletters and other investor related information please click here.
Search our site
Investor Information
Our Science
LCT’s patented encapsulation technology is a world first success.
More InformationInternational Team
LCT’s global team includes independent directors with extensive biotechnology, theraputics and capital raising experience.
More InformationDiabeCell®
Natural neo-natal porcine islets encapsulated in an alginate gel and transplanted for the treatment of insulin-dependent diabetes.
More Information